Welcome to our dedicated page for Phibro Animal SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phibro Animal Health Corporation filings document current reports for an animal health and mineral nutrition operating company with Class A common stock registered on Nasdaq. Recent Form 8-K disclosures cover operating results and financial guidance, quarterly dividends on Class A and Class B common stock, and amendments to the company’s credit agreement.
The filing record also includes Regulation FD disclosure about Brazilian rules for performance enhancing feed additives containing antimicrobials, including virginiamycin and bacitracin, and governance reports covering board and executive leadership changes. These filings frame PAHC’s disclosure record around operating performance, capital allocation, debt capacity, product regulation and public-company governance.
PHIBRO ANIMAL HEALTH CORP director E. Thomas Corcoran bought 10,000 shares of Class A Common Stock in an open-market purchase. The weighted average price was $31.77 per share, with trade prices ranging from $31.66 to $31.85.
After this transaction, he directly holds 41,459 shares, which includes 1,459 shares acquired through a dividend reinvestment plan sponsored by his broker.
BFI Co., LLC and Jack C. Bendheim filed an amended Schedule 13D for Phibro Animal Health, disclosing a new Rule 10b5-1 sales plan. The plan allows Goldman Sachs to sell up to 750,000 shares of Class A Common Stock through March 17, 2027, with the first possible trade date on September 16, 2026.
As of May 22, 2026, BFI beneficially owns 19,552,186 shares of common stock, equal to 48.2% of the Class A Common Stock on an as-converted basis, through 56,152 Class A shares and 19,496,034 Class B shares. If all plan shares are sold, BFI would still hold 56,152 Class A shares and 18,746,034 Class B shares.
Barclays PLC filed an amended Schedule 13G/A reporting beneficial ownership of 263,695 shares of Phibro Animal Health Corp-A common stock, representing 1.27% of the class. The filing shows Barclays has sole voting and sole dispositive power over the reported shares. The amendment is signed by a Barclays director on 05/14/2026.
Phibro Animal Health insider-related entity BFI Co., LLC sold a net 18,608 shares of Class A Common Stock in open-market transactions from May 5–7, 2026, at weighted average prices ranging from about $47 to $58 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted by BFI on December 11, 2025. BFI now holds 56,152 shares indirectly associated with President and CEO Jack Bendheim, who also directly holds 16,840 shares and disclaims beneficial ownership of BFI’s holdings beyond his pecuniary interest.
Phibro Animal Health Corporation reported solid growth for its third quarter ended March 31, 2026. Net sales were $383.5 million, up 10% from a year earlier, driven mainly by a 13% increase in Animal Health revenue to $291.2 million. Net income rose to $24.0 million, a 15% increase, and diluted EPS grew 16% to $0.59. Adjusted EBITDA was $60.8 million, up 11%, while adjusted net income reached $31.2 million and adjusted diluted EPS climbed 19% to $0.76.
Gross margin improved to 32.8% from 30.1%, reflecting higher volume, favorable mix and pricing. The company updated fiscal 2026 guidance to net sales of $1.46–$1.50 billion and adjusted EBITDA of $247–$255 million, noting higher midpoints across key measures. Phibro also highlighted a regulatory development in Brazil affecting certain antimicrobial products, a $125 million increase in its revolving credit facility to $435 million, and the launch of its Sustainable Solutions Platform, including VERRATAIN Verified Sustainability Solutions.
Phibro Animal Health delivered higher Q3 2026 results, with net sales of $383.5 million, up 10% from $347.8 million, and net income of $24.0 million versus $20.9 million. Diluted EPS rose to $0.59 from $0.51.
For the nine months, net sales climbed to $1.12 billion, up 22%, while net income more than doubled to $78.0 million, driven largely by the October 2024 Zoetis portfolio acquisition and strong Animal Health growth. Animal Health revenue reached $864.7 million, up 29%, led by medicated feed additives.
Leverage remains meaningful, with term loans of about $625.9 million and revolver borrowings of $115.0 million, pushing interest expense, net, to $34.2 million for the nine months. The company highlights geopolitical exposure in Israel and regulatory risks around carbadox in the U.S. and antimicrobial growth promoters in Brazil.
Phibro Animal Health Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.12 per share. The dividend applies to both its Class A and Class B common stock. It will be paid on June 24, 2026 to stockholders of record as of the close of business on June 3, 2026.
Phibro Animal Health Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.12 per share. The dividend applies to both its Class A and Class B common stock. It will be paid on June 24, 2026 to stockholders of record as of the close of business on June 3, 2026.
Phibro Animal Health Corp reported that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A Common Stock in open-market transactions on April 28–30, 2026. The weighted average sale prices ranged from about $52.65 to $56.69 per share, with all sales executed under a Rule 10b5-1 trading plan adopted by BFI on December 11, 2025. Following these sales, BFI’s reported indirect holdings were 74,760 shares, and Bendheim also directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health Corporation entered into Amendment No. 1 to its Credit Agreement with Coöperatieve Rabobank U.A. and other lenders on April 28, 2026. This amendment increases the company’s revolving credit commitment by $125,000,000, raising the facility from $310,000,000 to an aggregate commitment of $435,000,000.
The larger revolving credit line represents a new direct financial obligation for Phibro and is documented as a material definitive agreement. The full text of Amendment No. 1 is filed as Exhibit 10.1 and is incorporated by reference for detailed terms, representations and warranties.
Phibro Animal Health Corp reports institutional ownership disclosure. Vanguard Capital Management reports beneficial ownership of 1,043,822 shares, representing 5.06% of common stock as of 03/31/2026. The filing attributes 152,539 shares of sole voting power and 1,043,822 shares of sole dispositive power to Vanguard Capital Management and affiliated business divisions.